Abingworth announced it has wrapped up Abingworth Bioventures VII with $315 million in commitments. The fund is Abingworth’s 12th to invest multi-stage life sciences companies in the United States and Europe. The firm, which has offices in London, Menlo Park and Boston, said it raised the fund from endowments, foundations, fund-of-funds, family offices, healthcare corporations, insurance companies and pension plans in the U.S., Europe and Asia.
